Cyclophosphamide with Adjuvant Chemotherapeutic Drugs Induces Epigenetic Changes in Hepatocellular Carcinoma Cells

Hussein Sabit1*, Arwa S. Abdel-Sattar1, Shima E. Abdel-Ghany2, Asmaa M. Abushady3, Osama A. M. Said1

1 College of Biotechnology, Misr University for Science and Technology, Giza, Egypt, 2 Research and Development Center, Misr University for Science and Technology, Giza, Egypt, 3 Department of Genetics, Fac. Agric., Ain Shams University, Cairo Egypt.

* Corresponding author: mailto: hussein.sabit@must.edu.eg.

Abstract: Cancer remains the major health threat worldwide; therefore, the extensive search for potent cancer-controlling agents are still a big demand. Hepatocellular carcinoma (HCC) is a type of cancer widespread in the developing countries. In the present study, the role of Cyclophosphamide and drug combinations (including Erlotinib, Temozolomide, Vorinostat, and Sodium Phenylbutyrate) as DNA methyltransferase (DNMT) and Histone deacetylase (HDAC) inhibitors was evaluated. Two concentrations of each drug i.e., 3µM and 5µM for one incubation period of 72 h were applied. Trypan blue test was used to count the number of viable cells before and after treatments. DNA degradation assay was employed to evaluate the effect of Cyclophosphamide and a combination of drugs on the integrity of genomic DNA. Global methylation was also quantified via measuring the concentration of 5-Methylcytidin in the treated and un-treated HCC cells. Data obtained indicated that treating HCC cells with Cyclophosphamide either alone or in combination with other drugs has resulted in a significant decrease in the number of viable cells. Meanwhile, global DNA methylation data analysis showed that three combinations have resulted in hypomethylating the whole genome of HCC cells (Cyclophosphamide with Erlotinib, Cyclophosphamide with Sodium Phenylbutyrate, and Cyclophosphamide with Vorinostat). Although in vitro data need to be tested on the pre-clinical level, the best combination, Cyclophosphamide combined with Sodium Phenylbutyrate, might be recommended to be used in treating HCC in vivo.


Keywords: Hepatocellular carcinoma, HCC, Epigenetics, chemotherapeutic drugs.

1. Introduction

Cancer is a complicated disease that shows itself in various forms, all these forms were marked by the same uncontrolled proliferation of cells (Allen and Chen, 2013). Hepatocellular carcinoma (HCC) is viewed as the main reason for death worldwide in men and women with around 6% of all new cancer cases diagnosed around the world (Buonaguro et al., 2013).

Tumors appear when mutations accumulate within cells and eventually prompt uncontrolled cell growth. These changes can be brought on by external factors, for example, hepatitis infection, or by internal factors, such as hypermethylation of tumor-silencing genes (Diederich et al., 2014). HCC is an aggressive disorder with a high rate of mortality and morbidity (Anestopoulo et al., 2015). If identified in the symptomatic stage, the patient has an untreated mean life expectancy of less than one month; even at this stage, the accessible medicines are constrained and ineffective (Lu et al., 2014).

DNA methylation plays an important role in many biological events and is associated with various diseases (Liu et al., 2015). Several factors may directly or indirectly regulate the dynamic distribution of DNA methylation and demethylation between intergenic and intragenic gene regions, which means that thereby controlling gene expression (Jiang et al., 2013). DNA methylation played a critical part in numerous biological events and is connected with different diseases (Liu et al., 2015), and have an essential role in the regulation of gene expression, as it is the first epigenetic change to occur on a given DNA strand (Mathiyalagan et al., 2014, Lopez-Ramirez and Nicoli, 2014).

CpG islands have direct ramifications for the understanding of DNA methylation patterns in typical conditions (Tao et al., 2014) and in some normal illness states (Stefansson et al., 2015), including cancer CpG island shores (Rhee et al., 2013) and first exons (Rao et al., 2013) is known to play crucial part in the gene expression patterns in all human malignancies.

DNA hypermethylation is characterized by hyperactivity of the DNA methyltransferase enzymes, and gene expression of Dnmt3b, and concurrent methylation-dependent silencing of various epigenetic biomarker genes (Roll et al., 2013). The methylation of promoter DNA sequences suppresses the binding of several transcription-related proteins (Paonessa et al.,
2013). The methyl groups project into the major groove of DNA; through the direct interference of the binding of specific transcription factors that have methylated CpG(s) within their response elements (Hagiwara et al., 2012; Haerter et al., 2014).

Cyclophosphamide (CP), works as an alkylating chemotherapeutic drug and is used in cancer therapy (Mittal et al., 2014), by activating a robust innate anti-tumor immunity (Waxman and Wu, 2014). Although the advances of traditional therapies, such as surgery, transplantation, and use of radiotherapy, the prognosis of HCC neoplasm has not considerably improved over the past few years (Giordano and Columbano, 2014). Recent randomized clinical trials (RCTs) have demonstrated survival benefits for combination therapy (Gresham et al., 2014). In addition, the study of epigenetic mechanisms of gene regulation offers a novel approach for innovative diagnosis and treatment of different types of cancer (Cock-Rada and Weitzman, 2013). However, the aim of the present study is to test the role of cyclophosphamide combined with different chemotherapeutic drugs in changing the genome-wide methylating profile in HCC cells.

2. Materials and Methods

Cell line maintenance

Hepatocellular carcinoma cell line (HepG2) was purchased from the Holding Company for Vaccines and Biological Products (VACSERA), Cairo, Egypt. The cells were maintained in RPMI 1640 media supplemented with 10% Fetal Bovine Serum (FBS) and 1% antibiotic mix. Cells were grown in humidified conditions with 5% CO₂ at 37°C.

Cell viability test

Prior subjecting the cells to any treatment, Trypan blue test was performed to assess the number of viable cells. Briefly, 100 µL of cell suspension was mixed with 100 µL of trypan blue and the mix was applied to the haemocytometer slide and then measured under inverted microscope. Trypan blue was also performed after applying the chemotherapeutic drugs.

Chemotherapeutic drugs

Cyclophosphamide, Erlotinib, Sodium Phenylbutyrate, Vorinostat, and Temozolomide were purchased from Santa Cruz Biotech. (USA). A stock of both 3µM and 5µM of each drug was prepared and used for the treatment of the HCC cells.

Drug application

Five different drugs/drug combinations were applied. In a 12-well tissue culture plate, 1 x 10⁶ cells/well was inoculated and left for 24 h before applying the drug/drug combinations. Combinations were mixed separately and added to the wells containing the HCC according to the design represented in Table 1.

| Table (1): The combination and the concentrations used in the present study. |
|------------------|------------------|------------------|------------------|------------------|
| C                | CY (3µM)         | CY +S (3µM)      | CY +E (3µM)      |
| CY +V (3µM)      | CY +T (3µM)      | CY (5µM)         | CY +S (5µM)      |
| CY +E (5µM)      | CY +V (5µM)      | CY +T (5µM)      | C                |

C: Control, CY: Cyclophosphamide, S: Sodium Phenylbutyrate, E: Erlotinib, V: Vorinostat, and T: Temozolomide.

DNA extraction

Genomic DNA was extracted from treated and non-treated cells for the downstream analysis i.e., DNA degradation assay and methylation quantification in the malignant cells after being treated with the drugs. Extraction was done using Cell Biolab DNA extraction kit (USA) according to the kit’s instructions.

DNA degradation assay

After being extracted, a suitable volume of the eluted DNA was migrated on a 1.4% agarose gel. Gels were subjected to 5 V for 5 minutes and then to 120 V for about 30 min. Gels were photographed after being stained with Ethidium Bromide.

Quantification of whole genome methylation

Global methylation in the treated and un-treated cells was measured using MethylFlash quantification kit (Cell Biolabs, USA) with minor modifications. Briefly, the extracted genomic DNA was applied to the assay wells. Wells were washed and the capture antibody was added, and the chromatin was enzymatically sheared to allow the antibody to bind to the assay wells. The antibody was immunoprecipitated. The flouro assay solution was added after washing and then the signals were measured immediately at 580 nm using plate reader. A standard curve was generated to calculate the concentrations of 5-Methylcytidin in the treated and untreated samples (Figure 1).

Statistical analysis

Statistical analyses were conducted by SAS 9 software (SAS Institute, Cary, NC). The analysis was performed according to the following model:

\[ y_{ijk} = \mu + a_i + b_j + e_{ijk} \]

Where \( \mu \) is the population mean, \( a_i \) is the effect of each of the five different drugs/drug combinations and \( b_j \) is the effect of the concentration within each treatment. The criterion for significance was set at \( p < 0.01 \) for all tests.
3. Results and Discussion

Cell viability after treatment

Trypan blue test was performed to measure the number of viable cells after being treated with the drug/drug combinations (Wang et al., 2012). Figure (2) shows the differences in the number of viable cells between treated and untreated cells. The obtained data indicated that all of the treatments resulted in a significant decrease in the number of viable cells compared to the control (Table 2). It was shown elsewhere (Vives et al., 2013; Kayal et al., 2015; Mondi et al., 2015) that the combined treatment of the malignant cells might result in prolonged effect and also in higher efficiency in terms of enforcing malignant cell to commit apoptosis. Our data indicated that out of the combined chemotherapeutics, Cyclophosphamide and Erlotinib (3µM), was the most efficient combination followed by Cyclophosphamide and Sodium Phenylbutyrate (5µM). Meanwhile, Cyclophosphamide alone (5µM) was more efficient in inducing apoptosis compared to its lower concentration (3µM). Data obtained indicated that not all the combinations had the same profile, as the HCC cells might undergo specific internal changes, which is combination- or dose-mediated (Morris et al., 2013; de la Torre et al., 2015). The obtained profile could be attributed to the fact that Cyclophosphamide, as DNMT inhibitor, perform its function by attenuating and/or inhibiting the enzymatic activity of DNMTs, and subsequently hypomethylate the HCC-related tumor suppressor gene, which led eventually to enforce the malignant cells to commit apoptosis (Bassiouny et al., 2010; Zheng et al., 2010). On the other hand, Erlotinib, as HDAC inhibitor, helps the maintenance of a specific level of acetylation in the promotor region of the HCC-related tumor suppressor genes. This mechanism has led to euchromatinize the promotor region and hence to accumulate the product of these genes, which in turn enforce the cells to commit apoptosis (Lai et al., 2005; Choudhari et al., 2007).

Table (2): The mean values of Duncan's Multiple Range Test for cell viability of control and treated cells.

<table>
<thead>
<tr>
<th>Treat./ Conc.</th>
<th>N</th>
<th>Mean</th>
<th>Duncan Grouping</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>4</td>
<td>387500</td>
<td>A</td>
</tr>
<tr>
<td>CY+E (C2)</td>
<td>4</td>
<td>264375</td>
<td>B</td>
</tr>
<tr>
<td>CY+S (C1)</td>
<td>4</td>
<td>212500</td>
<td>C</td>
</tr>
<tr>
<td>CY+T (C2)</td>
<td>4</td>
<td>187500</td>
<td>D</td>
</tr>
<tr>
<td>CY+T (C1)</td>
<td>4</td>
<td>175000</td>
<td>D</td>
</tr>
<tr>
<td>CY (C1)</td>
<td>4</td>
<td>175000</td>
<td>D</td>
</tr>
<tr>
<td>CY+V (C1)</td>
<td>4</td>
<td>175000</td>
<td>D</td>
</tr>
<tr>
<td>CY+V (C2)</td>
<td>4</td>
<td>137500</td>
<td>E</td>
</tr>
<tr>
<td>CY (C2)</td>
<td>4</td>
<td>125000</td>
<td>E F</td>
</tr>
<tr>
<td>CY+S (C2)</td>
<td>4</td>
<td>112500</td>
<td>G F</td>
</tr>
<tr>
<td>CY+E (C1)</td>
<td>4</td>
<td>100000</td>
<td>G</td>
</tr>
</tbody>
</table>


DNA degradation assay

DNA fragmentation is considered a powerful tool to identify the effect of treating cell lines with chemotherapeutic drugs (Muller et al., 2010). The extracted genomic DNA was subjected to electrophoresis to assess the degradation of DNA due to the treatments. Figure (3) shows the smears of degraded DNA in different treatments.

As shown in Figure (3), all treatments have resulted in a severe degradation of the genomic DNA content of the cells. This DNA fragmentation might be due to the inactivation of caspase-associated DNase inhibitor (CADi) (Yuste et al., 2005; Yan et al., 2009), which releases the CAD to degrade DNA, or, on the other hand, via suppressing DNA repair mechanisms (Groselj et al., 2013). Cyclophosphamide and other drugs might be involved in this mechanism (Sarder et al., 2015). Data obtained showed that the combination of Cyclophosphamide with Erlotinib was very efficient in inducing DNA fragmentation. In addition, the combination of Cyclophosphamide and Vorinostat resulted in an obvious smear.

Quantification of Global DNA methylation

In the present study, the global methylation level in all treated and untreated HCC cells was evaluated. In this assay, 5-Methylcytidin concentration was measured as indicator for the occurrence of hypo/hypermethylation as a result of the treatments. The obtained data (Figure 4 and Table 3) showed that...
the HCC responded differently to the dose and combination of the applied chemotherapeutic drugs. As shown in Figure (4), the combination of Cyclophosphamide with Sodium Phenylbutyrate (3µM) has resulted in a significant hypomethylation, while using the same combination in a higher concentration (5µM) resulted in a significant hypermethylation ($P<0.01$). The same profile was obtained when Cyclophosphamide combined with Erlotinib and Vorinostat was used, where the lower concentration (3µM) have led to hypomethylate the whole genome of HCC cells and the higher concentration (5µM) have oppositely hypermethylated the cell’s genome. This might be attributed to the synergetic action of Sodium Phenylbutyrate when combined with Cyclophosphamide. Several studies (Phillips and Griffin 2007; Iannitti and Palmieri, 2011; Gresham et al., 2014) have indicated the same profile. Furthermore, seven drug/drug combinations have resulted in moderate to severe hypermethylation. One of the most effective drug combinations that activated the DNMT was the combination of Cyclophosphamide and Sodium Phenylbutyrate (5µM). This was concluded from the numbers of viable cells generated in the present study. The hypermethylation status profiled in the HCC cells might has been occurring in some anti-apoptotic gene, and this could enforce the cells to commit apoptosis (Hervouet et al., 2010; Stone et al., 2013).

Table (3): Mean values of Duncan's Multiple Range Test for quantification of global DNA methylation.

<table>
<thead>
<tr>
<th>Treat. Conc.</th>
<th>N</th>
<th>Mean</th>
<th>Duncan Grouping</th>
</tr>
</thead>
<tbody>
<tr>
<td>CY+S (C2)</td>
<td>4</td>
<td>26536</td>
<td>A</td>
</tr>
<tr>
<td>CY+V (C2)</td>
<td>4</td>
<td>17479</td>
<td>B</td>
</tr>
<tr>
<td>CY (C1)</td>
<td>4</td>
<td>14401</td>
<td></td>
</tr>
<tr>
<td>CY+T (C2)</td>
<td>4</td>
<td>11974</td>
<td>D</td>
</tr>
<tr>
<td>CY+T (C1)</td>
<td>4</td>
<td>8067</td>
<td>E</td>
</tr>
<tr>
<td>CY (C2)</td>
<td>4</td>
<td>7949</td>
<td>E</td>
</tr>
<tr>
<td>CY+E (C2)</td>
<td>4</td>
<td>5521</td>
<td>F</td>
</tr>
<tr>
<td>C</td>
<td>4</td>
<td>4693</td>
<td>F</td>
</tr>
<tr>
<td>CY+V (C1)</td>
<td>4</td>
<td>4515</td>
<td>G</td>
</tr>
<tr>
<td>CY+E (C1)</td>
<td>4</td>
<td>3254</td>
<td>H</td>
</tr>
<tr>
<td>CY+S (C1)</td>
<td>4</td>
<td>-2469</td>
<td>I</td>
</tr>
</tbody>
</table>


Figure (1): A standard curve of the relationship between OD and concentration of 5-Methylcitidine.
Figure (2): The differences in the number of viable cells between treated and untreated cells. C: Control, Cy: Cyclophosphamide, S: Sodium Phenylbutyrate, E: Erlotinib, V: Vorinostat, and T: Temozolomide. I: concentration of 3µM and II: concentration of 5µM.

Figure (3): DNA degradation assay. C: Control, Cy: Cyclophosphamide, E: Erlotinib, T: Temozolomide, S: Sodium Phenylbutyrate, and V: Vorinostat.

Figure (4): Levels of 5-Methylcytidin in nM after treating HCC cells with different drugs. C: Control, Cy: Cyclophosphamide, S: Sodium Phenylbutyrate, E: Erlotinib, and T: Temozolomide. I: concentration of 3µM and II: concentration of 5µM.
Data could also be viewed in a dose-wise perspective to elucidate the effect of the drug dose on the HCC cell proliferation (Figure 5). Meanwhile, the presented data indicated that applying Cyclophosphamide in lower concentration (3µM) resulted in hypermethylation of the whole genome of the hepatocellular carcinoma cells (Figure 6). The higher concentration of the same drug (5µM) yielded a lower methylation rate, despite being higher than the control. When combined with Sodium Phenylbutyrate in lower concentration (3µM), cyclophosphamide induced a severe hypomethylation, while when the same combination was applied in higher concentration (5µM), it induced severe hypermethylation.

This might indicate that the combination should be used in lower concentration (Greten et al., 2010; Reguart et al., 2014). In addition, when Cyclophosphamide was applied combined with Erlotinib, the lower concentration caused hypomethylation of the whole genome of the HCC cells, while the high concentration yielded more methyl groups added to the CpG dinucleotides. This also indicated that the desired hypomethylation pattern could be obtained by using the lower concentrations of the combined drugs. The same profile has been noticed when Cyclophosphamide was combined with other drugs, i.e., Vorinostat and Temozolomide (Zhang et al., 2011).

Figure 6 shows the changes in global methylation patterns due to different treatments.

In conclusion, the hypo- and hypermethylation rates obtained were not able to assign a specific drug combination as the best one, but rather both mechanisms could lead to control the proliferation of the HCC cells. Although, in vitro data always need to be confirmed on the clinical level, the present study revealed that we could rely on the combination composed of Cyclophosphamide and Sodium Phenylbutyrate in in vivo treatment of HCC.
References
18. Kayal S., D. Biswajit, S.L. Cyriac, B. Badhe, D. Kadambari, B. Bharathi, D. Swaruparani, S. Gopinath and K. Dhanraj. Comparison of neoadjuvant chemotherapy (NACT) with 5-fluorouracil, epirubicin (100mg), cyclophosphamide (FEC100) followed by docetaxel (D) (75mg) versus adriamycin and cyclophosphamide (AC) followed by docetaxel (100mg) in locally advanced breast cancer (LABC): A randomized clinical study. Journal of Clinical Oncology. 2015; Vol 33, No 15.
22. Lu D., C. Han and T. Wu. 15-PGDH inhibits hepatocellular carcinoma growth through 15-keto-PGE2/PPARγ-mediated activation of


12/1/2015